$1.46 +0.04 (2.64%)

Galmed Pharmaceuticals Ltd. (GLMD)

Galmed Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company focused on the development of innovative therapies for liver diseases. The company's lead product candidate, Aramchol, is a bile acid derivative developed for the treatment of non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). Galmed also explores other therapeutic options targeting liver and metabolic conditions.

🚫 Galmed Pharmaceuticals Ltd. does not pay dividends

Company News

Galmed Announces Digital Asset Management Strategy to Enhance Capital Efficiency and Drive Shareholder Value
Benzinga • Prnewswire • August 25, 2025

Galmed Pharmaceuticals plans to invest up to $10 million in digital assets, engaging Tectona Ltd. to manage a new crypto treasury strategy aimed at enhancing capital efficiency and shareholder value.

Madrigal Pharmaceuticals Wins Approval for the First Drug Targeting the Multibillion-Dollar NASH Market. Is the Stock a Screaming Buy?
The Motley Fool • [email protected] (Keith Speights) • March 17, 2024

Madrigal's Rezdiffra will have the NASH market all to itself -- at least for a while.

MDGL NVO GALT IQV VKTX ETNB
Galmed Pharmaceuticals (GLMD) Moves to Buy: Rationale Behind the Upgrade
Zacks Investment Research • Zacks Equity Research • September 14, 2022

Galmed Pharmaceuticals (GLMD) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.